文献速递中枢神经肿瘤放疗胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗

免疫检查点抑制剂联合放疗的毒性:系统综述与荟萃分析

Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2020-07-24

该系统综述与荟萃分析纳入51项研究共15398例患者,比较免疫检查点抑制剂联合放疗(ICI+RT)与单纯ICI治疗的毒性。结果显示两组3-4级毒性发生率相当(16.3% vs 22.3%),但抗CTLA-4治疗和黑色素瘤患者毒性增加。ICI+RT在中枢神经系统黑色素瘤转移、非小细胞肺癌和前列腺癌中安全。

要点

  • ICI+RT与单纯ICI的3-4级毒性发生率相当,分别为16.3%和22.3%。
  • 抗CTLA-4治疗和黑色素瘤患者中ICI+RT毒性增加。
  • ICI+RT在中枢神经系统黑色素瘤转移、非小细胞肺癌和前列腺癌中安全。

核心结论

  • 随机效应模型显示,在中枢神经系统黑色素瘤转移、非小细胞肺癌和前列腺癌中,ICI+RT与单纯ICI的3-4级毒性相当,ICI+RT对这些癌症的未来临床试验是安全的。

研究设计与样本

  • 遵循PRISMA的系统综述,检索MEDLINE(PubMed)和国家综合癌症网络指南中的研究,主要结局为3级及以上毒性。
  • 纳入51项研究共15398例患者,其中35项单纯ICI研究(n=13956),16项ICI+RT研究(n=1442)。
  • 采用DerSimonian和Laird方法的随机效应模型进行荟萃分析,使用I2统计量和Cochran Q检验评估异质性,漏斗图和Egger检验评估发表偏倚。

主要发现

  • ICI+RT的3-4级毒性发生率为16.3%(95%CI 11.1-22.3%),单纯ICI为22.3%(95%CI 18.1-26.9%)。
  • 按放疗时机和照射部位分层未见显著差异,但抗CTLA-4治疗和黑色素瘤显示毒性增加。
  • 单纯ICI和ICI+RT的5级毒性分别为1.1%和1.9%。
  • 存在显著异质性,但无发表偏倚。

关键数值与推荐

  • 单纯ICI的纳入标准:比较免疫治疗与安慰剂、化疗或替代免疫治疗的III/IV期试验。
  • ICI+RT的纳入标准:具有ICI+RT治疗臂的前瞻性或回顾性研究。

临床怎么用

  • 在中枢神经系统黑色素瘤转移、非小细胞肺癌和前列腺癌中,ICI+RT的3-4级毒性与单纯ICI相当,可支持这些癌症的临床试验开展。
  • 抗CTLA-4治疗和黑色素瘤患者接受ICI+RT时需注意毒性增加。

局限性

  • 存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Immune checkpoint inhibitor with radiation therapy (ICI + RT) is under investigation for improved patient outcome, so we performed a systematic review/meta-analysis of toxicities for ICI + RT compared to immune checkpoint inhibitor (ICI) therapy alone. MATERIALS AND METHODS: A PRISMA-compliant systematic review of studies in MEDLINE (PubMed) and in the National Comprehensive Cancer Network guidelines was conducted, with primary outcome grade 3 + toxicity. Criteria for ICI alone were: phase III/IV trials that compared immunotherapy to placebo, chemotherapy, or alternative immunotherapy; and for ICI + RT: prospective/retrospective studies with an arm treated with ICI + RT. Meta-analysis was performed by random effects models using the DerSimonian and Laird method. The I2 statistic and Cochran's Q test were used to assess heterogeneity, while funnel plots and Egger's test assessed publication bias. RESULTS: This meta-analysis included 51 studies (n = 15,398), with 35 ICI alone (n = 13,956) and 16 ICI + RT studies (n = 1,442). Our models showed comparable grade 3-4 toxicities in ICI + RT (16.3%; 95% CI, 11.1-22.3%) and ICI alone (22.3%; 95% CI, 18.1-26.9%). Stratification by timing of radiation and irradiated site showed no significant differences, but anti-CTLA-4 therapy and melanoma showed increased toxicity. The grade 5 toxicities were 1.1% and 1.9% for ICI alone and ICI + RT respectively. There was significant heterogeneity, but not publication bias. CONCLUSIONS: The random effects model showed comparable grade 3-4 toxicity in using ICI + RT compared to ICI alone in CNS melanoma metastases, NSCLC, and prostate cancer. ICI + RT is safe for future clinical trials in these cancers.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sha CM, Lehrer EJ, Hwang C, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2020. PMID: 32717359. doi:10.1016/j.radonc.2020.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。